Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.27 USD | +5.83% | -6.57% | +61.88% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Financials (USD)
Sales 2024 * | 49.9M | Sales 2025 * | 58.87M | Capitalization | 298M |
---|---|---|---|---|---|
Net income 2024 * | -38M | Net income 2025 * | -36M | EV / Sales 2024 * | 5.91 x |
Net cash position 2024 * | 2.63M | Net Debt 2025 * | 15.47M | EV / Sales 2025 * | 5.32 x |
P/E ratio 2024 * |
-6.67
x | P/E ratio 2025 * |
-8.01
x | Employees | 135 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.07% |
Latest transcript on Aquestive Therapeutics, Inc.
1 day | +5.83% | ||
1 week | -6.57% | ||
Current month | -2.68% | ||
1 month | -16.37% | ||
3 months | +23.40% | ||
6 months | +94.64% | ||
Current year | +61.88% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Barber
CEO | Chief Executive Officer | 48 | 07-06-30 |
A. Toth
DFI | Director of Finance/CFO | 65 | 20-12-30 |
Stephen Wargacki
CTO | Chief Tech/Sci/R&D Officer | 46 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 22-08-09 |
Santo Costa
BRD | Director/Board Member | 78 | 15-11-30 |
Gregory Brown
CHM | Chairman | 70 | 07-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 3.27 | +5.83% | 1,501,156 |
24-05-10 | 3.09 | -6.08% | 2,032,874 |
24-05-09 | 3.29 | +6.65% | 2,093,599 |
24-05-08 | 3.085 | -8.73% | 2,748,314 |
24-05-07 | 3.38 | -3.43% | 1,575,339 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.88% | 281M | |
+29.98% | 684B | |
+30.34% | 568B | |
-3.52% | 361B | |
+18.59% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.09% | 166B |
- Stock Market
- Equities
- AQST Stock